Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 13/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.34 |
| ▸ | HTR3B | O95264 | 1/20 | 0.34 |
| ▸ | HTR3A | P46098 | 1/20 | 0.34 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.34 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30196175 | 1.00 | KIF11 (0.45) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL29648906 | 0.85 | MAPK1 (0.44) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL60206 | 0.85 | MAPK1 (0.44) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL1555041 | 0.85 | MAPK1 (0.47) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL1493109 | 0.81 | CYP3A4 (0.55) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL13788639 | 0.81 | KIF11 (0.41) | KIF11TDP1CYP3A4KDM1ACYP11B1 | |
| SCHEMBL856525 | 0.80 | MAPK1 (0.61) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL9859233 | 0.80 | MAPK1 (0.43) | KIF11MAPK1TDP1CYP3A4TRPA1 | |
| SCHEMBL7177146 | 0.79 | MAPK1 (0.46) | MAPK1TDP1CYP3A4TRPA1TSHR | |
| SCHEMBL29824353 | 0.78 | MAPK1 (0.52) | MAPK1TDP1CYP3A4TRPA1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021067801-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | IFM DUE, INC. (US) | 2021-04-08 | — | — | WO | disclosed |
| EP-1487841-B1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBVIE INC (US) | 2014-01-15 | — | — | EP | disclosed |
| US-7560552-B2 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES (US) | 2009-07-14 | — | — | US | disclosed |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | MICHAELIDES MICHAEL R | 2006-12-07 | — | — | US | disclosed |
| EP-1487841-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | Abbott Laboratories (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBVIE INC. | 2004-01-22 | — | — | US | disclosed |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABBOTT LABORATORIES | 2003-12-04 | — | — | US | disclosed |
| WO-2003080625-A1 | THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-10-02 | — | — | WO | disclosed |
| US-4782091-A | INSECTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-01 | — | — | US | disclosed |
| US-4782090-A | Benzoyl(thio)urea pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 1988-11-01 | — | — | US | disclosed |
| EP-0268943-A1 | Benzoyl(thio)ureas | BAYER AG (DE) | 1988-06-01 | — | — | EP | disclosed |
| EP-0268952-A1 | Benzoyl(thio) ureas | BAYER AG (DE) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014756-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIF11 2343/4885MAPK1 212/4885TDP1 613/4885 |
| US-20060276490-A1 | Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors | ABL1, LCK, ERBB2 | KIF11 2243/4885MAPK1 436/4885TDP1 787/4885 |
| US-20030225273-A1 | Thiopyrimidine and isothiazolopyrimidine kinase inhibitors | ABL1, ERBB2, LCK | KIF11 2343/4885MAPK1 212/4885TDP1 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.